Login to Your Account



SciClone Climbs On Phase II Zadaxin Data In Skin Cancer

By Jennifer Boggs


Tuesday, December 26, 2006
Positive interim survival data from a Phase II skin cancer study of Zadaxin, an immunomodulator, pushed SciClone Pharmaceuticals Inc.'s stock up more than 38 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription